Accumulation of mutant polyglutamine proteins in intraneuronal inclusions is a hallmark of polyglutamine diseases. Impairment of protein clearance systems and sequestration of clearance-related proteins into inclusions occur in many protein folding diseases, including polyglutamine diseases. The ubiquitin-binding and proteasome adaptor protein UBQLN2 participates in protein homeostasis and localizes to inclusions in various neurodegenerative diseases. Employing mouse models and human brain tissue of Huntington's disease (HD) and spinocerebellar ataxia type 3 (SCA3), we show that UBQLN2 is selectively recruited to inclusions in HD but not SCA3. Consistent with this result, in a cell-based system mutant HTT interacts with UBQLN2 through the UBA domain while the SCA3 disease protein ATXN3, a deubiquitinating enzyme, does not interact with UBQLN2. Differential recruitment of UBQLN2 to aggregates in HD and SCA3 underscores the heterogeneity of inclusions in polyglutamine diseases and suggests that components of neuronal protein quality control may be differentially perturbed in distinct polyQ diseases.
Introduction
Polyglutamine (polyQ) neurodegenerative diseases are caused by abnormally long polyQ tracts that promote protein misfolding and aggregation of the mutant disease proteins. A shared neuropathological hallmark of polyglutamine diseases is accumulation of ubiquitinpositive inclusions in susceptible brain regions, typically within neurons (Orr and Zoghbi, 2000; Paulson et al., 1997) . Two cellular systems are principally responsible for the clearance of misfolded proteins, the ubiquitin-proteasome pathway (UPP) and the autophagy-lysosome system (Nijholt et al., 2011) . Impairment of both systems and sequestration of clearance-related proteins into aggregates formed by disease proteins may contribute to polyglutamine disease pathogenesis (Rubinsztein, 2006; Zhang and Saunders, 2009; Zhang et al., 2014) .
Here we investigate the involvement of the clearance-related protein ubiquilin-2 (UBQLN2) in polyglutamine disease. UBQLNs are a family of multi-functional proteins that contain an N-terminal ubiquitin-like (UBL) domain and a C-terminal ubiquitin-associated (UBA) domain (Lee and Brown, 2012). The human genome encodes four UBQLNs, numbered 1 through 4; (Lee and Brown, 2012) of which UBQLNs 1, 2 and 4 are expressed in the brain (Safren et al., 2015) . The presence of UBA and UBL domains, which respectively bind ubiquitinated proteins and the proteasome (Ko et al., 2004; Lee and Brown, 2012; Walters et al., 2002) , supports the view that UBQLNs act as shuttle proteins targeting proteins for proteasomal degradation (Lim et al., 2009) . UBQLNs may also regulate autophagy-lysosome function (Rothenberg et al., 2010) among other potential functions (Gilpin et al., 2015) . The best studied family member, UBQLN1, also known as protein linking integrinassociated protein and cytoskeleton-1 (PLIC-1), is reported to interact with the polyQ disease proteins Huntingtin (HTT) and ataxin-3 (ATXN3) (Doi et al., 2004; Heir et al., 2006) . Overexpression of UBQLN1 in numerous model systems of Huntington's disease (HD) delays polyQ aggregation and increases lifespan (Rothenberg et al., 2010; Safren et al., 2014; Wang et al., 2006; Wang and Monteiro, 2007) , while knockdown of UBQLN1 exacerbates polyQ toxicity in nematode models (Wang et al., 2006) . UBQLN1 also interacts with Alzheimer's disease (AD) associated
